Yaron Naos - Protalix Biotherapeutics Senior Vice President - Operations
| PLX Stock | USD 2.17 0.07 3.13% |
President
Mr. Yaron Naos is Senior Vice President Operations of the Company. He joined Protalix Ltd. in 2004 as Senior Director, Operations, and, since 2008, has served as the Companys Vice President for Production. He has a wealth of handson experience and knowledge in the field of pharmaceutical development since 2018.
| Age | 61 |
| Tenure | 7 years |
| Professional Marks | MBA |
| Address | Science Park, Karmiel, Israel, 2161401 |
| Phone | 972 4 902 8100 |
| Web | https://www.protalix.com |
Yaron Naos Latest Insider Activity
Tracking and analyzing the buying and selling activities of Yaron Naos against Protalix Biotherapeutics stock is an integral part of due diligence when investing in Protalix Biotherapeutics. Yaron Naos insider activity provides valuable insight into whether Protalix Biotherapeutics is net buyers or sellers over its current business cycle. Note, Protalix Biotherapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Protalix Biotherapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Yaron Naos over three months ago Acquisition by Yaron Naos of 100000 shares of Protalix Biotherapeutics at 1.1 subject to Rule 16b-3 |
Protalix Biotherapeutics Management Efficiency
The company has Return on Asset of (0.0747) % which means that on every $100 spent on assets, it lost $0.0747. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.2718) %, meaning that it generated no profit with money invested by stockholders. Protalix Biotherapeutics' management efficiency ratios could be used to measure how well Protalix Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Protalix Biotherapeutics' Return On Tangible Assets are fairly stable compared to the past year. Return On Capital Employed is likely to rise to 0.32 in 2025, whereas Return On Equity is likely to drop 0.21 in 2025. At this time, Protalix Biotherapeutics' Other Current Assets are fairly stable compared to the past year. Return On Tangible Assets is likely to rise to 0.12 in 2025, whereas Total Assets are likely to drop slightly above 51 M in 2025.Similar Executives
| Found 9 records | PRESIDENT Age | ||
| Les Tari | Cidara Therapeutics | N/A | |
| Michel Dahan | Akebia Ther | 45 | |
| Stephen Machatha | Aldeyra | 47 | |
| William Jones | Corvus Pharmaceuticals | 59 | |
| Jeffrey JD | Lexicon Pharmaceuticals | 59 | |
| Laura Navalta | Cidara Therapeutics | ||
| Jeffrey Stein | Cidara Therapeutics | 70 | |
| Steven Burke | Akebia Ther | 63 | |
| Erik Verner | Corvus Pharmaceuticals | 59 | |
Management Performance
| Return On Equity | -0.27 | ||||
| Return On Asset | -0.0747 |
Protalix Biotherapeutics Leadership Team
Elected by the shareholders, the Protalix Biotherapeutics' board of directors comprises two types of representatives: Protalix Biotherapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Protalix. The board's role is to monitor Protalix Biotherapeutics' management team and ensure that shareholders' interests are well served. Protalix Biotherapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Protalix Biotherapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Eyal MBA, CFO, VP | ||
| Yaron Naos, Senior Vice President - Operations | ||
| Yael Fellous, Vice Resources | ||
| Dror Bashan, President CEO |
Protalix Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Protalix Biotherapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.27 | ||||
| Return On Asset | -0.0747 | ||||
| Profit Margin | (0.21) % | ||||
| Operating Margin | 0.22 % | ||||
| Current Valuation | 143.21 M | ||||
| Shares Outstanding | 73.63 M | ||||
| Shares Owned By Insiders | 14.52 % | ||||
| Shares Owned By Institutions | 6.34 % | ||||
| Number Of Shares Shorted | 5.05 M | ||||
| Price To Earning | (1.23) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Protalix Stock Analysis
When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.